<DOC>
	<DOCNO>NCT00328120</DOCNO>
	<brief_summary>The primary objective study assess tolerability 500mg fulvestrant postmenopausal woman hormone receptor positive , advanced recurrent breast cancer</brief_summary>
	<brief_title>Faslodex 500mg Multiple Dose Tolerability Study BC Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Provision write informed consent Postmenopausal woman fulfil one follow criterion : Histological cytological confirmation breast cancer Estrogen receptor positive ( ER+ ) progesterone receptor positive ( PgR+ ) . Having receive one follow therapy advance recurrent breast cancer 2 regimens hormonal therapy immunotherapy 2 regimen chemotherapy , etc</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Faslodex</keyword>
</DOC>